Correction to: Neuropsychopharmacology https://doi.org/10.1038/s41386-021-01004-7, published online 05 April 2021
The original version of this article unfortunately mischaracterized the pharmacology of ibogaine.
The corrected text is as follows:
The recent report in Nature from Cameron et al. (2021)4 offers tantalizing evidence that non-hallucinogenic psychedelic compounds may possess beneficial actions. The authors started with ibogaine, a powerful hallucinogenic plant alkaloid with low affinity for serotonin and dopamine transporters, as well as kappa opioid receptors4,5. They then synthesized a novel analog of ibogaine called tabernanthalog (TBG). TBG is shown to have unique pharmacological properties and to lack many of the negative side effects of ibogaine.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Thompson, S.M. Correction: Optimizing psychedelic compounds for neuropsychiatric therapy. Neuropsychopharmacol. 46, 1545 (2021). https://doi.org/10.1038/s41386-021-01021-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41386-021-01021-6